Form 4: Avidity Biosciences CEO Exercises, Sells Shares

Avidity Biosciences President and CEO, Sarah Boyce, exercised stock options and subsequently sold 25,000 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Summary

• Sarah Boyce, President and CEO of Avidity Biosciences, Inc., engaged in an option exercise and subsequent sale of common stock.
• On August 28, 2025, Ms. Boyce exercised options to acquire 25,000 shares of common stock at an exercise price of $1.24 per share.
• Immediately following the exercise, Ms. Boyce sold 25,000 shares of common stock at a weighted-average price of $49.388 per share, with individual sales ranging from $49.23 to $49.52.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted by Ms. Boyce on August 15, 2024.
• Following these transactions, Ms. Boyce directly beneficially owns 305,871 shares of common stock and 1,072,015 stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While an insider sale can sometimes be viewed negatively, the transaction was pre-planned under a 10b5-1 plan, indicating a routine liquidity event rather than a reaction to adverse company news. The significant profit realized by the executive from the option exercise is a positive for the individual, reflecting past company performance and equity value.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, indicating a planned liquidity event rather than a reaction to new company-specific negative news.
• The significant difference between the option exercise price ($1.24) and the sale price ($49.388) demonstrates substantial value creation for the executive from previously granted equity awards.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors, potentially signaling a lack of further upside, though this is often a routine liquidity event for executives.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic direction.

Management Comments

• The option exercise and sales reported were effected pursuant to a Rule 10b5-1 trading plan previously adopted on August 15, 2024 by the Reporting Person.

Industry Context

This filing reports a routine insider transaction for an executive at a publicly traded biotechnology company. Such transactions are common for executives managing their personal finances and equity holdings, particularly when options vest and become exercisable.

Corporate Governance

Stakeholder Impact

• Shareholders: May view this as a routine, pre-planned transaction by a key executive, which is common for liquidity and diversification purposes. The volume of shares sold is not exceptionally large relative to the company's market capitalization.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction (option exercise and sale) by the CEO. It does not contain new material information about the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is consistent with executive compensation practices and personal financial planning, and the volume is not indicative of a significant shift in the executive's confidence in the company's long-term prospects. Therefore, a 'hold' recommendation is appropriate, pending further fundamental analysis.

Keywords

Avidity Biosciences, RNA, Sarah Boyce, Insider Transaction, Form 4, Stock Option Exercise, 10b5-1 Plan, Equity Sales